Entrada Therapeutics (TRDA) EBITDA (2020 - 2026)

Entrada Therapeutics has reported EBITDA for 7 years, with the latest figure at -$40.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 137.85% year-over-year to -$40.1 million; the trailing twelve-month figure through Mar 2026 stood at -$166.3 million (down 753.11% YoY), and the FY2025 full-year result was -$143.1 million, down 318.78% from the prior year.
• EBITDA for Q1 2026 stood at -$40.1 million, down from -$39.1 million in the prior quarter.
• The five-year high for EBITDA was $54.9 million in Q2 2024, with the low at -$43.9 million in Q3 2025.
• Average EBITDA over 5 years is -$12.9 million, with a median of -$23.2 million recorded in 2022.
• Year-over-year, EBITDA surged 538.39% in 2024 and sank 33835.34% in 2025.
• Tracing TRDA's EBITDA over 5 years: stood at -$23.9 million in 2022, then surged by 63.02% to -$8.9 million in 2023, then soared by 101.31% to $116000.0 in 2024, then slumped by 33835.34% to -$39.1 million in 2025, then retreated by 2.53% to -$40.1 million in 2026.
• The last three EBITDA figures came in at -$40.1 million (Q1 2026), -$39.1 million (Q4 2025), and -$43.9 million (Q3 2025), per Business Quant data.

Peer Comparison